Details for Patent: 10,857,161

Which drugs does patent 10,857,161 protect, and when does it expire?

Patent 10,857,161 protects AGAMREE and is included in one NDA.

This patent has fifty-two patent family members in twenty-five countries.

Summary for Patent: 10,857,161

Title:	Non-hormonal steroid modulators of NF-kB for treatment of disease
Abstract:	Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.
Inventor(s):	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
Assignee:	Reveragen Biopharma Inc
Application Number:	US16/226,061
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 10,857,161

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Catalyst Pharms	AGAMREE	vamorolone	SUSPENSION;ORAL	215239-001	Oct 26, 2023		RX	Yes	Yes	10,857,161		Y			TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

International Family Members for US Patent 10,857,161

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2805720		301273	Netherlands
European Patent Office	2805720		CA 2024 00018	Denmark
European Patent Office	2805720		PA2024518	Lithuania
European Patent Office	2805720		LUC00349	Luxembourg